Vericel Corporation (NASDAQ:VCEL) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.
As disclosed in the Original Report, on May15, 2017, the Company
entered into the Distribution Agreement. The description of the
Distribution Agreement included in the Original Report is hereby
incorporated by reference into this Form8-K/A. The Distribution
Agreement is attached to this Form8-K/A as Exhibit10.1.
Item 1.02. Termination of a Material Definitive
Agreement.
As disclosed in the Original Report, on May15, 2017, the Company
entered into the Fifth Amendment. The information set forth in
Item 1.02 of the Original Report, including the description of
the Fifth Amendment, is incorporated by reference as if fully set
forth herein. The Fifth Amendment is attached to this Form8-K/A
as Exhibit10.2.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits.
|
ExhibitNo. |
|
Description |
|
10.1 * |
Distribution Agreement by and between Orsini Pharmaceutical |
|
|
10.2 * |
Fifth Amendment, dated May15, 2017, to the Services |
* Confidential treatment has been requested for portions of this
exhibit. These portions have been omitted from the exhibit to
this Current Report on Form8-K/A and submitted separately to the
Securities and Exchange Commission.
Filed herewith.
About Vericel Corporation (NASDAQ:VCEL)
Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy. Vericel Corporation (NASDAQ:VCEL) Recent Trading Information
Vericel Corporation (NASDAQ:VCEL) closed its last trading session up +0.03 at 3.03 with 424,176 shares trading hands.